The diversifying epilepsy pipeline is finally addressing inhibitory deficits that sodium channel drugs can’t touch
The diversifying epilepsy pipeline is finally addressing inhibitory deficits that sodium channel drugs can’t touch
The donor-derived cell therapy is designed to be infused alongside a stem cell transplant, aiming to reduce a …
The bispecific antibody paired with lenalidomide showed a statistically significant improvement over standard care in patients with relapsed …
Phase 3 ARTISTRY-1 and ARTISTRY-2 data support an NDA for a single-tablet HIV regimen combining a capsid inhibitor …
A single dose of the lysergide orally disintegrating tablet achieved statistically significant MADRS improvement at six weeks compared …
Capivasertib plus abiraterone and prednisone clears regulatory hurdle for a molecularly defined patient population with limited prior options, …
Tebipenem pivoxil hydrobromide clears regulatory hurdle on resubmission, offering hospitalized patients an oral alternative to intravenous imipenem-cilastatin
The acquisition, announced in March and targeting Centessa’s orexin receptor agonist programme, signals Lilly’s intention to build a …
Shionogi’s ensitrelvir becomes the only approved oral option for preventing COVID-19 following known exposure, filling a gap left …
Arvinas’s vepdegestrant (VEPPANU) marks a regulatory milestone as the first proteolysis-targeting chimera to win FDA approval, offering a …
Already a subscriber? Log in